CellChorus announces the 2023 TIMING Grant Challenge

Applications will be accepted through December 10, 2023

PRESS RELEASE

HOUSTON, Texas — November 1, 2023 — CellChorus Inc., the leader in applying artificial intelligence to visually evaluate how thousands of individual cells perform over time, announced today the opening of the 2023 TIMING™ Grant Challenge. The Challenge seeks applicants with research, development and manufacturing projects that will benefit from dynamic single-cell analysis and present a significant innovation or advance in human health. CellChorus will award up to ten TIMING assays conducted at the CellChorus Innovation Lab in Houston, Texas. The assays will be run in early 2024.

“One of the exciting elements of the TIMING platform is its applicability to a wide range of therapeutic areas, cell types, and applications,” said Daniel Meyer, CEO of CellChorus. “We continue to be amazed at the novel approaches that experts in the field are taking to improve the lives of people here in the U.S. and around the world.”

The Challenge will accept submissions from researchers, investigators and manufacturing experts at both not-for-profit and commercial entities. CellChorus encourages submissions from investigators who are New and Early Career Investigators, are from underreprestented communities, and are located in HUBzones. A key goal of the Challenge is to identify and reward novel and compelling uses for dynamic single-cell data on cell phenotype, migration, proliferation, contact dynamics, morphology, viability, potency, biomolecule secretion, subcellular activity, and other single-cell temporal readouts.

Submissions will be selected based on a review by the CellChorus team and feedback from a group of experts including:

  • Julien Bradley (CEO of Axion)

  • Laurence Cooper, MD, PhD (Co-founder of CellChorus)

  • Mick Correll (President of Genospace)

  • Krishna Komanduri, MD (Physician-in-Chief at the UCSF Comprehensive Cancer Center)

  • Stan Rose, PhD (former CEO of Transplant Genomics and NimbleGen Systems)

Additional information is available at cellchorus.com/2023-challenge:

About CellChorus

CellChorus is the leader in applying artificial intelligence (AI) to visually evaluate how thousands of individual immune cells, such as T cells and NK cells, perform over time. The company applies Time lapse Imaging Microscopy in Nanowell Grids™ (TIMING™) with neural network-based AI to identify cells and evaluate their activity, including how they move, activate, kill and survive. The patent-protected CellChorus platform can link TIMING data and insights with information from other analysis modalities such as single-cell RNA sequencing and flow cytometry to provide a comprehensive understanding of cellular function, state and phenotype for the life sciences industry. Please visit cellchorus.com for more information.

Company Contact:
Daniel Meyer
Chief Executive Officer
CellChorus Inc.
TIMING@cellchorus.com

SOURCE CellChorus Inc.